Last year, the EU-funded consortium ENATRANS (Enabling NAnomedicine TRANSlation) launched the Nanomedicine Translation Advisory Board (TAB), the first European accelerator in Nanomedicine 100% sponsored by European Commission to provide support to ambitious European Nanomedicine projects.
The TAB offers a free advisory service to fast-track promising projects to the market, based on the high-level experience of seasoned Pharma/Biotech translation experts.
The TAB has already received a total of 23 applications from 10 countries in Europe and EU associated countries. 20 of these projects are being actively supported by the TAB to increase their chances of translation for the benefit of Health worldwide.
The Second Call to the TAB is now open to companies, public and private research entities, and other organisations leading Nanomedicine projects in Europe, which target global clinical needs.
Applications for the Second Call are due until 8 May 2016. Projects to be selected will be invited to attend the Second TAB-In Sessions, a series of individual meetings with experts to be held on the 28 June 2016, in Basel (Switzerland).
Applications should be submitted through the following link: http://www.nanomedtab.eu/?apply.
Further information about the TAB and the experts can be found at http://www.nanomedtab.eu.